- Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition2021 | 2. lékařská fakulta
- Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial2023 | 1. lékařská fakulta
- Role BRAF/MEK inhibice u metastazujícího maligního melanomu - kazuistika2016 | Lékařská fakulta v Hradci Králové
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial2018 | 1. lékařská fakulta
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial2018 | 1. lékařská fakulta
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib2015 | Publikace bez příslušnosti k fakultě